Trial Profile
CA225103: A phase II study of a combination of cetuximab and capecitabine in patients with metastatic colorectal cancer after progression on previous fluoropyrimidine containing therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cetuximab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 25 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Dec 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
- 01 Jan 2008 Status changed from recruiting to in progress.